The introduction of captopril-the first orally active inhibitor of angiotensin converting enzyme-into clinical medicine has been an example of skilled, purposeful pharmacological development; and the drug has been found to have a wider therapeutic range than might have been supposed initially. '-9 The small but distinct fall in blood pressure seen in normal people treated with captopril supported data from earlier studies suggesting that peripheral plasma concentrations of angiotensin II are within a pressor range. Captopril has been shown to be an effective antihypertensive agent in hypertension accompanying renovascular disease, and, when combined with loop diuretics, in previously intractable hypertension. As sole treatment in essential hypertension, its antihypertensive action is similar to that of beta-adrenoceptor blockers or thiazide diuretics; it appears particularly useful in essential hypertension when given together with a thiazide. when the drug is stopped. The combination of captopril with large doses of loop diuretics in patients with impaired renal function can further raise serum concentrations of urea and creatinine. Hyperkalaemia is unusual but has been seen occasionally. One small double blind study found no evidence of a euphoriant effect of captopril'9; such trials might usefully be extended and refined.
Some problems that had been expected with treatment with captopril have not materialised. For example, patients on long term dosage may attain very high circulating concentrations of angiotensin I and renin. Indeed, because renin substrate levels fall with captopril, measurements of plasma renin activity will underestimate the rise of renin concentration,20 and increases in circulating renin may be a good deal higher than appeared from some of the early reports. So far, however, no adverse effects attributable to angiotensin I or renin have been identified. Furthermore-at least with captopril 150 mg three times daily-despite the very high resulting concentrations of renin and angiotensin I, no evidence has been found of any breakthrough of converting enzyme inhibition and consequent generation of angiotensin II or angiotensin III in the circulation. 2' We believe that the introduction of orally active converting enzyme inhibitors has been a major advance in cardiovascular treatment. The past five years have seen a widening of their therapeutic range, but this has yet to be fully delineated. Problems associated with the use of these agents have been identified and substantially resolved. The next five years should see their potential exploited. The irritable bowel syndrome accounts for a third to a half of referrals to gastroenterologists,' yet remarkably little is understood of its pathogenesis. Anyone who looks after patients with the syndrome knows that they vary greatly, both in their symptoms and in their response to treatment. Indeed, experts are trying hard to identify subgroups with more constant symptom patterns and-they hope-a more predictable response to treatment.
This urge to subdivide and classify the irritable bowel syndrome dominated an international workshop on the disease held at Chateau Impney in June this year. One important step, made in 1962, was when Chaudhary and Truelove separated a group with painless diarrhoea from the majority who had pain and a variable bowel habit, the spastic colon group.2 Since then we have learned that pain may arise in the small intestine as well as the colon and that patients often have symptoms arising from the oesophagus and gastroduodenum.3 4 Hence most gastroenterologists now speak of the irritable bowel or even the irritable gut5 rather than of the irritable colon.
One of the problems in defining varieties of the irritable bowel syndrome is the lack of objective evidence of gut dysfunction in this condition. Patients with the irritable bowel syndrome who attend hospital have a high prevalence of neurotic traits and some regard them as merely oversensitive and overanxious people who notice and complain about normal abdominal sensations and about normal variations in bowel habit. This is unfair, since obvious spasm may sometimes be seen on barium radiographs (as well as on manometry), and the excess excretion of mucus is clear evidence of colonic malfunction, if not irritation. Nevertheless, patients with the irritable bowel syndrome are oversensitive to distension of the bowel,6 and they tend to make more of a fuss about minor ailments than other people.7
Classically the patient with the irritable bowel syndrome complains of alternating constipation and diarrhoea. This should be easy to document. What could be simpler than weighing the stools for several weeks and repeatedly measuring the passage time of radio-opaque pellets in a series of patients and then relating the findings to their symptoms ? That would at least indicate how far the patients' bowel function varies from normal and whether it does indeed swing from constipation to diarrhoea and back again. Such a study has never been reported, and even in normal people the scanty data show that the function of the colon varies wildly, not only among individuals but even in the same normal person at
